PRKCD and endometrial cancer: (14) reported that ER-α36 could rapidly activate the PKCδ/ERK pathway in response to E2, leading to an increase of cyclin D1/cyclin-dependent kinase 4, resulting in the promotion of cell cycle progression and proliferation in endometrial cancer.